{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:00:23Z","timestamp":1794632423269,"version":"4.9.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1245\/s10434-021-11236-y","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T15:03:39Z","timestamp":1643382219000},"page":"3694-3708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)"],"prefix":"10.1245","volume":"29","author":[{"given":"Alexander C. J.","family":"van Akkooi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina J.","family":"Hieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ariyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore V. M. A.","family":"Asero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7522-6173","authenticated-orcid":false,"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Caraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Scott","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Pedreira","family":"Duprat Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Faries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"Grunhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gyorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M. C.","family":"Klop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn P. M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerwin F.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro A. E.","family":"Testori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike T.","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.","family":"Zuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick I.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Neoadjuvant Melanoma Consortium (INMC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"11236_CR1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u201392.","journal-title":"CA Cancer J Clin"},{"key":"11236_CR2","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa060992","volume":"355","author":"DL Morton","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307\u201317.","journal-title":"N Engl J Med"},{"key":"11236_CR3","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1245\/s10434-011-1741-0","volume":"18","author":"AP van der Ploeg","year":"2011","unstructured":"van der Ploeg AP, van Akkooi AC, Schmitz PI, et al. Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol. 2011;18:3300\u20138.","journal-title":"Ann Surg Oncol"},{"key":"11236_CR4","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1245\/s10434-016-5396-8","volume":"23","author":"MF Madu","year":"2016","unstructured":"Madu MF, Wouters MW, Klop WM, et al. Clinical prognostic markers in stage IIIB melanoma. Ann Surg Oncol. 2016;23:4195\u2013202.","journal-title":"Ann Surg Oncol"},{"key":"11236_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jso.24635","volume":"116","author":"MF Madu","year":"2017","unstructured":"Madu MF, Schopman JHH, Berger DMS, et al. Clinical prognostic markers in stage IIIC melanoma. J Surg Oncol. 2017;116:244\u201351.","journal-title":"J Surg Oncol"},{"key":"11236_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"11236_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122\u201333.","journal-title":"N Engl J Med"},{"key":"11236_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109\u201317.","journal-title":"Lancet"},{"key":"11236_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"11236_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","journal-title":"Lancet Oncol"},{"key":"11236_CR11","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"11236_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"11236_CR13","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316.","journal-title":"N Engl J Med"},{"key":"11236_CR14","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694\u2013703.","journal-title":"N Engl J Med"},{"key":"11236_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107\u201314.","journal-title":"N Engl J Med"},{"key":"11236_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358\u201365.","journal-title":"Lancet"},{"key":"11236_CR17","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877\u201388.","journal-title":"N Engl J Med"},{"key":"11236_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444\u201351.","journal-title":"Lancet"},{"key":"11236_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30\u20139.","journal-title":"N Engl J Med"},{"key":"11236_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603\u201315.","journal-title":"Lancet Oncol"},{"key":"11236_CR21","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835\u201344.","journal-title":"Lancet"},{"issue":"Supplement 4","key":"11236_CR22","doi-asserted-by":"publisher","first-page":"S1173","DOI":"10.1016\/j.annonc.2020.08.2275","volume":"31","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Mandala M, Ferrucci PF, et al. First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). Ann Oncol. 2020;31(Supplement 4):S1173\u20134.","journal-title":"Ann Oncol"},{"key":"11236_CR23","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer R, Lebbe C, Atkinson V, et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020;26:1557\u201363.","journal-title":"Nat Med"},{"key":"11236_CR24","unstructured":"USFDA: FDA grants regular approval to nivolumab for adjuvant treatment of melanoma 2017."},{"key":"11236_CR25","unstructured":"USFDA: FDA approves pembrolizumab for adjuvant treatment of melanoma."},{"key":"11236_CR26","unstructured":"USFDA: FDA approves dabrafenib plus trametinib for adjuvant treatment of melanoma with BRAF V600K or V600K mutations."},{"key":"11236_CR27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355.","journal-title":"N Engl J Med"},{"key":"11236_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med"},{"key":"11236_CR29","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med"},{"key":"11236_CR30","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med"},{"key":"11236_CR31","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol. 2018;36:3441\u20139.","journal-title":"J Clin Oncol"},{"key":"11236_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","volume":"119","author":"AMM Eggermont","year":"2019","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer. 2019;119:1\u201310.","journal-title":"Eur J Cancer"},{"key":"11236_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer R, Brase JC, Garrett J, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21:358\u201372.","journal-title":"Lancet Oncol"},{"issue":"33","key":"11236_CR34","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1200\/JCO.20.00198","volume":"38","author":"R Seth","year":"2020","unstructured":"Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020; 38(33):3947\u20133970. https:\/\/doi.org\/10.1200\/JCO.20.00198","journal-title":"J Clin Oncol"},{"key":"11236_CR35","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1884\u2013901.","journal-title":"Ann Oncol"},{"key":"11236_CR36","doi-asserted-by":"crossref","unstructured":"Hauschild A, Dummer R, Santinami M, Atkinson V, Mandal\u00e0 M, Kirkwood JM, Chiarion Sileni V, Larkin JM, Nyakas M, Dutriaux C, Haydon AM. Long-term benefit of adjuvant dabrafenib\u00a0+\u00a0trametinib (D\u00a0+\u00a0T) in patients (pts) with resected stage III BRAF V600\u2013mutant melanoma: five-year analysis of COMBI-AD 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.10001"},{"key":"11236_CR37","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600\u2013mutant stage III melanoma. J Clin Oncol. 2018;36:3441\u20139.","journal-title":"J Clin Oncol"},{"key":"11236_CR38","doi-asserted-by":"crossref","unstructured":"Long GV, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D\/IV melanoma (CheckMate 915). In: Clin Cancer Res Presented at: AACR Annual Meeting 2021; April 10\u201315, 2021; Virtual. Abstract CT004, 2021.","DOI":"10.1158\/1538-7445.AM2021-CT004"},{"key":"11236_CR39","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019;20:e378\u201389.","journal-title":"Lancet Oncol"},{"key":"11236_CR40","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29:1861\u20138.","journal-title":"Ann Oncol"},{"key":"11236_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27:301\u20139.","journal-title":"Nat Med"},{"key":"11236_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"19","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018;19:181\u201393.","journal-title":"Lancet Oncol"},{"key":"11236_CR43","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24:1649\u201354.","journal-title":"Nat Med"},{"key":"11236_CR44","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655\u201361.","journal-title":"Nat Med"},{"key":"11236_CR45","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20:948\u201360.","journal-title":"Lancet Oncol"},{"key":"11236_CR46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 2019;20:961\u201371.","journal-title":"Lancet Oncol"},{"key":"11236_CR47","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25:454\u201361.","journal-title":"Nat Med"},{"key":"11236_CR48","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1245\/s10434-020-08566-8","volume":"27","author":"AJ Spillane","year":"2020","unstructured":"Spillane AJ, Menzies AM, van Akkooi ACJ. The landmark series: Neoadjuvant Systemic Therapy (NAST) for stage 3 melanoma patients\u2014a potential paradigm shift in management. Ann Surg Oncol. 2020;27:2188\u2013200.","journal-title":"Ann Surg Oncol"},{"key":"11236_CR49","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1200\/JCO.2021.39.15_suppl.9502","volume":"39","author":"R Amaria","year":"2021","unstructured":"Amaria R, Postow M, Tetzlaff MT, et al. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. J Clin Oncol. 2021;39:9502.","journal-title":"J Clin Oncol"},{"key":"11236_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27:256\u201363.","journal-title":"Nat Med"},{"issue":"15","key":"11236_CR51","doi-asserted-by":"publisher","first-page":"10002","DOI":"10.1200\/JCO.2020.38.15_suppl.10002","volume":"38","author":"CU Blank","year":"2020","unstructured":"Blank CU, Reijers ILM, Pennington T, et al. First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38(15):10002.","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"11236_CR52","first-page":"v851","volume":"30","author":"R Dummer","year":"2019","unstructured":"Dummer R, Gyorki D, Hyngstrom J, et al. Primary 2-year (yr) results of a phase 2, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma. Ann Oncol. 2019;30(suppl 5):v851\u2013934.","journal-title":"Ann Oncol"},{"key":"11236_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jamcollsurg.2014.02.019","volume":"219","author":"ME Egger","year":"2014","unstructured":"Egger ME, Brown RE, Roach BA, et al. Addition of an iliac\/obturator lymph node dissection does not improve nodal recurrence or survival in melanoma. J Am Coll Surg. 2014;219:101\u20138.","journal-title":"J Am Coll Surg"},{"key":"11236_CR54","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1245\/s10434-019-07810-0","volume":"26","author":"MA Henderson","year":"2019","unstructured":"Henderson MA, Gyorki D, Burmeister BH, et al. Inguinal and ilio-inguinal lymphadenectomy in management of palpable melanoma lymph node metastasis: a long-term prospective evaluation of morbidity and quality of life. Ann Surg Oncol. 2019;26:4663\u201372.","journal-title":"Ann Surg Oncol"},{"key":"11236_CR55","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1245\/s10434-010-1203-0","volume":"17","author":"MB Faries","year":"2010","unstructured":"Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010;17:3324\u20139.","journal-title":"Ann Surg Oncol"},{"key":"11236_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/bjs.11168","volume":"106","author":"B Schermers","year":"2019","unstructured":"Schermers B, Franke V, Rozeman EA, et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. Br J Surg. 2019;106:519\u201322.","journal-title":"Br J Surg"},{"key":"11236_CR57","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","volume":"13","author":"GR Varadhachary","year":"2006","unstructured":"Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035\u201346.","journal-title":"Ann Surg Oncol"},{"key":"11236_CR58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1477-2574.2012.00451.x","volume":"14","author":"FG Rocha","year":"2012","unstructured":"Rocha FG, Helton WS. Resectability of colorectal liver metastases: an evolving definition. HPB (Oxford). 2012;14:283\u20134.","journal-title":"HPB (Oxford)"},{"key":"11236_CR59","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1749-4486.2009.01884.x","volume":"34","author":"A Kreeft","year":"2009","unstructured":"Kreeft A, Tan IB, van den Brekel MW, et al. The surgical dilemma of \u2018functional inoperability\u2019 in oral and oropharyngeal cancer: current consensus on operability with regard to functional results. Clin Otolaryngol. 2009;34:140\u20136.","journal-title":"Clin Otolaryngol"},{"key":"11236_CR60","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.annonc.2020.07.016","volume":"31","author":"MT Tetzlaff","year":"2020","unstructured":"Tetzlaff MT, Adhikari C, Lo S, et al. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020;31:1569\u201379.","journal-title":"Ann Oncol"},{"key":"11236_CR61","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","volume":"16","author":"MA Henderson","year":"2015","unstructured":"Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1049\u201360.","journal-title":"Lancet Oncol"},{"key":"11236_CR62","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/SLA.0000000000004893","volume":"274","author":"SA Blankenstein","year":"2021","unstructured":"Blankenstein SA, Rohaan MW, Klop WMC, et al. Neoadjuvant cytoreductive treatment with BRAF\/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR: a prospective, single arm, open-label phase II trial. Ann Surg. 2021;274:383\u20139.","journal-title":"Ann Surg"},{"key":"11236_CR63","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejso.2006.10.032","volume":"33","author":"AC van Akkooi","year":"2007","unstructured":"van Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol. 2007;33:102\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"11236_CR64","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322.","journal-title":"N Engl J Med"},{"key":"11236_CR65","doi-asserted-by":"publisher","first-page":"O154","DOI":"10.1111\/codi.12490","volume":"16","author":"TF Eriksen","year":"2014","unstructured":"Eriksen TF, Lassen CB, Gogenur I. Treatment with corticosteroids and the risk of anastomotic leakage following lower gastrointestinal surgery: a literature survey. Colorectal Dis. 2014;16:O154\u201360.","journal-title":"Colorectal Dis"},{"key":"11236_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cell.2019.12.009","volume":"180","author":"D Dickson","year":"2020","unstructured":"Dickson D, Johnson J, Bergan R, et al. The master observational trial: a new class of master protocol to advance precision medicine. Cell. 2020;180:9\u201314.","journal-title":"Cell"},{"key":"11236_CR67","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","volume":"6","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6:519.","journal-title":"JAMA Oncol"},{"key":"11236_CR68","unstructured":"Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval by United States Food and Drug Administration: Center for Drug Evaluation and Research; 2020: FDA-2012-D-0432."},{"key":"11236_CR69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549\u201355.","journal-title":"Nature"},{"issue":"2","key":"11236_CR70","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1245\/s10434-021-11112-9","volume":"29","author":"TJ Hieken","year":"2021","unstructured":"Hieken TJ, Price DL, Piltin MA, et al. Surgeon assessment of the technical impact of neoadjuvant systemic therapy on operable stage III melanoma. Ann Surg Oncol. 2021;29(2):780\u2013786. https:\/\/doi.org\/10.1245\/s10434-021-11112-9","journal-title":"Ann Surg Oncol"},{"key":"11236_CR71","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo SP, Russell J, Hassel JC, et al. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): preliminary data from an ongoing study. Abstract 9530. J Clin Oncol Suppl. 2017.","DOI":"10.1200\/JCO.2017.35.15_suppl.9530"},{"key":"11236_CR72","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374\u201385.","journal-title":"Lancet Oncol"},{"key":"11236_CR73","doi-asserted-by":"publisher","first-page":"e001076","DOI":"10.1136\/jitc-2020-001076","volume":"8","author":"S Levy","year":"2020","unstructured":"Levy S, Aarts MJB, Eskens F, et al. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. J Immunother Cancer. 2020;8:e001076.","journal-title":"J Immunother Cancer"},{"key":"11236_CR74","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","volume":"37","author":"P Nghiem","year":"2019","unstructured":"Nghiem P, Bhatia S, Lipson EJ, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37:693\u2013702.","journal-title":"J Clin Oncol"},{"key":"11236_CR75","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374:2542\u201352.","journal-title":"N Engl J Med"},{"key":"11236_CR76","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","volume":"21","author":"MR Migden","year":"2020","unstructured":"Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21:294\u2013305.","journal-title":"Lancet Oncol"},{"key":"11236_CR77","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1200\/JCO.20.00201","volume":"38","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 Trial. J Clin Oncol. 2020;38:2476\u201387.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1245\/s10434-022-11622-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000}}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-11236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-11236-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-11236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T22:03:46Z","timestamp":1651788226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-11236-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["11236"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-11236-y","relation":{"correction":[{"id-type":"doi","id":"10.1245\/s10434-022-11622-0","asserted-by":"object"}]},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1245\/s10434-022-11622-0","URL":"https:\/\/doi.org\/10.1245\/s10434-022-11622-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RAS has received fees for professional services from Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. DEG Advisory boards\u2014Amgen, Bayer, Q Biotics; Speaker Fee\u2014BMS. RPMS has received honoraria for advisory board participation from MSD, Novartis, and Qbiotics and speaking honoraria from BMS and Novartis. GVL is consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Evaxion Biotech A\/S, Hexel AG, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc., SkylineDX B.V., Specialised Therapeutics Australia Pty Ltd. ROB has received institutional research grants from Bristol-Myers Squibb (BMS) and SkyLineDx, speaker honoraria from Roche and Pfizer, and has served on advisory boards for Amgen, BD\/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme. MCL has received honoraria for advisory board participation from BMS. JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, travel support from GSK and Provectus Inc, and support for conference attendance from Novartis. GCK PI of Investigator Initiated Trial (IIT) sponsored by Merck. AAET travel support for meetings from Agenus. PR has received honoraria for lectures and Advisory Boards from Novartis, MSD, BMS, Roche, Bayer, Pierre Fabre, Sanofi, Merck, Blueprint Medicines. PAA has\/had a consultant\/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore, Seagen, iTeos. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Array, Sanofi and travel support from MSD. TJH Research funding (to her institution) from Genentech, SkylineDX. JPDN Speaker for BMS and MSD. JSZ Relevant to the work are advisory board for Merck, Novartis. MSB Institutional research support from Genentech (related to this work) and from Bristol-Myers Squibb, Immune Design, Pharmacyclics, Marker Therapeutics, Sorrento Therapeutics, Transgene, Viewpoint Molecular Targeting, and Merck (unrelated to this work). Unpaid consultant for Sorrento Therapeutics, Viewpoint Molecular Targeting, and TILT Biotherapeutics. MTT Past advisory board relationships with Myriad Genetics, Nanostring, Bristol Meyers and Seattle Genetics (all closed); currently performing central pathology review for a Merck sponsored trial. AMM Advisory Boards\u2014BMS, MSD, Novartis, Roche, Pierre-Fabre, Qbiotics. MBF Advisory boards\u2014BMS, Novartis, Merck, Sanofi, Nektar, Pulse Bioscience. HT has received consulting fees from Merck, BMS, Novartis, Genentech, Eisai, Iovance, Karyopharm and Boxer Capital, and research funding to institution from Merck, BMS, Novartis, Genentech, GSK. CUB Advisory role: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures. GMB: Sponsored Research Agreement, Olink Proteomics, Palleon Pharmaceuticals, InterVenn Biosciences; Scientific Advisory Board: Nektar Therapeutics, Novartis, Ankyra; Consulting: InterVenn, Merck. VKS: Dr. Sondak is a compensated consultant for Bristol Myers Squibb, Eisai, Merck, Novartis, Regeneron, and Replimune and receives research funding from Neogene Therapeutics. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}